Earlier or Faster? Impact of the IRA on Oncology Drug Development
The Inflation Reduction Act (IRA) complicates decision making in oncology drug development, where one asset is typically developed for multiple indications in a 'late-line first, larger opportunity in early-line later' sequence. Join us as we discuss rethinking the traditional paradigm.